GuruFocus - On July 1, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), sold 100 shares of the company at a price of $1,059.24 per share. The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 17,882 shares of Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets products for eye diseases, high low-density lipoprotein cholesterol, and inflammatory diseases among others, and has product candidates in development in other areas of high unmet medical need.
Over the past year, Arthur Ryan has sold a total of 1,100 shares of Regeneron Pharmaceuticals Inc and has not purchased any shares. The company's insider transaction history shows a total of 63 insider sells and no insider buys over the past year.
Shares of Regeneron Pharmaceuticals Inc were trading at $1,059.24 on the day of the sale, giving the company a market cap of approximately $115.11 billion. The price-earnings ratio of the company stands at 30.86, which is above both the industry median of 27.54 and the company's historical median.
The stock's valuation metrics show a GF Value of $733.14, indicating that the stock is significantly overvalued with a price-to-GF-Value ratio of 1.44.
This insider sale comes at a time when the stock price is significantly above its GF Value, suggesting that the insider might perceive the stock as being overvalued at current levels.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This content was originally published on Gurufocus.com
